TruScreen Raises Over NZ$4 Million with Oversubscribed Rights Issue
TruScreen Group has completed a substantially oversubscribed NZ$2.9 million rights issue, boosting total capital raised to over NZ$4 million. The funds are set to support the company’s global expansion in cervical screening technology.
- Rights issue oversubscribed by 15%
- Shares allotted at NZ$0.013 per share on 30 June
- Directors to seek approval for additional share allocation
- Total capital raised exceeds NZ$4 million including prior placement
- Funds aimed at capitalising on growth opportunities
Oversubscribed Rights Issue Boosts Capital
TruScreen Group Limited (NZX:TRU) has wrapped up its renounceable rights issue and shortfall bookbuild, receiving applications for 171.65 million shares, 15% above the 149.46 million shares initially offered. This strong demand means the company will allot shares at the offer price of NZ$0.013 (A$0.011) on 30 June 2026.
The rights issue entitlements will see 80.6 million shares allotted, with a further 68.8 million shortfall shares allocated based on shareholder holdings as of 28 May 2026. Beyond this, the board intends to seek shareholder approval to issue an additional 22.19 million shares at the same price, potentially increasing the capital raised further.
Capital Raise Surpasses NZ$4 Million
This latest capital raise complements a prior NZ$1.82 million placement, bringing the total funds raised to just over NZ$4 million. Chairman Tony Ho highlighted the significance of this backing, stating the company is "delighted with the strong support" and that the funds will enable TruScreen to capitalise on substantial opportunities in the year ahead.
TruScreen’s capital injections come as the company accelerates its global expansion, including new market entries and large-scale screening initiatives. The company’s AI-enabled cervical screening device, TruScreen Ultra®, is registered and approved for clinical use across multiple countries, underpinning its growth potential.
Shareholder Approval and Allocation Details
The final share allotments for the rights issue and shortfall are scheduled for 30 June 2026. The additional shares applied for beyond the rights offer require shareholder approval, with a general meeting expected around 28 July 2026 to consider this allocation.
Scaling of the shortfall shares will be proportional to holdings on the record date, ensuring equitable distribution among shareholders. The consistent offer and bookbuild price of NZ$0.013 per share maintains pricing integrity across the capital raise.
Positioning for Growth in Cervical Screening
TruScreen’s technology continues to gain regulatory approvals and endorsements, including CE marking and registrations with health authorities in Australia, China, the UK, and beyond. The company reported over 200,000 examinations performed in FY2024 and maintains a presence in 29 countries.
With this fresh capital, TruScreen is poised to expand its footprint further, supporting initiatives such as large-scale screening programs and regulatory compliance efforts. The company’s focus on AI-enabled, real-time cervical tissue abnormality detection positions it to address global health challenges in women’s health.
Bottom Line?
TruScreen’s oversubscribed rights issue and placement provide a solid capital foundation, but shareholder approval for additional shares remains a key upcoming milestone.
Questions in the middle?
- Will shareholder approval for the additional 22 million shares be secured without dilution concerns?
- How will TruScreen allocate the new funds across expansion, regulatory, and operational priorities?
- What impact will this capital raise have on TruScreen’s competitive positioning in emerging markets?
